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Background: Since the protection time by hepatitis B (HB) vaccination is unclear, the strategy of immunization of junior students who 
previously received hepatitis vaccine is controversial.
Objectives: This study aimed to determine the status of immunity to hepatitis B in junior medical, nursing and obstetrics students with 
different hepatitis B virus (HBV) vaccination patterns.
Patients and Methods: In an analytical cross-sectional study, 255 junior medical sciences students were tested for quantitative antibodies 
to hepatitis B surface antigen (anti-HBs). The proportion of protective immunity was compared in different vaccination patterns.
Results: Vaccination coverage rates were 74.1%. About half the participants didn’t show serological evidence of protective immunity; 
68.9% had their last shot more than 10 years ago and 30.4% had a vaccination history of five years or less (P < 0.001). Geometric mean 
level of anti-HBs titer among students, who had received a primary series vaccine at birth, was significantly lower than students who had 
started vaccination at an older age (P < 0.001). Also, analysis of variance for geometric mean of anti-HBs titer showed significant differences 
between groups based on injection time from the last shot (P < 0.001) (post hoc comparisons resulted in a P value of < 0.001 for birth versus 
< 5 year group, and P < 0.001 for the 5 to 10 year group). The lowest rate of non-protective level belonged to participants with complete 
three doses and a booster additional shot (27.1%). The final model for independent predictors of anti-HBs positive status was made by a 
binary logistic regression analysis. The model included presence of a booster dose, injection time from last shot, and discipline of study.
Conclusions: This study shows lower anti-HBs among students who were vaccinated at infancy compared to those vaccinated at older 
childhood or adolescence. Also, subsequent measurement of anti-HBs level at the time of entrance to university is recommended for all 
previously immunized students.
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1. Background
Hepatitis B virus (HBV) infection can be effectively pre-
vented by hepatitis B (HB) vaccination, therefore, the 
world health organization (WHO) has recommended 
that all infants should receive hepatitis B vaccine (1). 
Routine HB vaccination has been provided to all Iranian 
newborns since 1993, although it had already started in 
two provinces as a pilot since 1989 (2). Before establish-
ment of routine hepatitis B vaccination programs, HBV 
infection was common among the Iranian population 
with a prevalence of 3% for HBV chronic carriers (3, 4). 
Hepatitis B vaccination programs have resulted in a sig-
nificant decrease in acute and chronic HBV infections 
among children and adolescents in Iran (5). In 2007, 
catch-up vaccination of all 17-year-old Iranian adoles-
cents, who visited public healthcare providers was im-
plemented (6). At that time, a three-injection schedule 
was applied for vaccination (6, 7). Although vaccination 
against HBV has been routinely performed for high-risk 
groups (such as healthcare workers) since 1992, yet na-
tionwide population-based studies on HBV immune 
status of healthcare workers (HCWs) and its related fac-
tors are sparse in Iran (8). Studies from other counties 
have shown substantial reductions in the prevalence of 
chronic infection and the incidence of acute hepatitis B 
among HCWs in populations where routine infant vacci-
nation has been implemented (9). Protection time after 
infancy is unknown (10, 11). Studies have shown low or 
undetectable levels of antibodies to hepatitis B surface 
antigen (anti-HBs) in a range of 15 to 97% of infants be-
tween 10 to 19 years after primary vaccination (12-16). Un-
detectable anti-HBs (serological marker for protection 
after primary vaccination) does not necessarily show 
lack of immunity (17, 18). In low risk populations, prov-
ing long-term protection of vaccine is difficult and not 
recommended (19). However, in high-risk groups (i.e. 
HCWs), HBV immune memory must be proved by mea-
suring anti-HBs concentration (20). Immunity status of 
junior students who were vaccinated during infancy or 
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adolescence is important for avoiding occupational HBV 
transmission. Despite education and interventions, a re-
cent study reported a rate of 53% for needle stick injury 
in nurses, at least once in the past year (21). Although 
occupational hepatitis seroconversion is relatively rare, 
risks and associated costs of a blood exposure are seri-
ous and real. These costs include initial and follow-up 
treatment of the exposed person (22, 23), fear and anxi-
ety about possible consequences of an exposure and ab-
sence from work (24).
Romano et al. suggested that booster vaccination may 
be needed for situations where risks of contracting 
Hepatitis B virus (HBV) infection and becoming chronic 
are high (25). Also, failure to develop post-booster anam-
nestic response has been reported (as immune memory 
may wane during the second decade post-vaccination) 
(26). In addition, one sixth of vaccines were unable to 
respond to booster vaccination, having lost immuno-
logical memory (27). Individuals who lost immunologi-
cal memory may become vulnerable to HBV infection, 
especially in highly endemic regions where HBsAg carri-
ers are often positive for HBeAg, thus, highly infectious. 
Therefore, the need for a booster in this setting, where 
risk of acquiring infection and becoming chronic is 
high, should be considered (25). If this was the policy, 
booster should be given before immunological memory 
loss occurs. Due to a higher risk of transmission dur-
ing the clinical education period, HBV immune status 
should be evaluated before any contact with blood and 
could be offered when students start their education. 
At the same time, junior students have several different 
patterns of hepatitis immunization.
2. Objectives
This study aimed to determine the status of immunity 
to hepatitis B in junior medical, nursing and obstetrics 
students with different prior HBV vaccination patterns.
3. Patients and Methods
In an analytical cross-sectional study in 2012, we 
checked anti-HBs status in junior medical, nursing, and 
obstetrics students, who had not yet started their in-hos-
pital clinical education. All students were asked about re-
ceiving blood products, living with chronic HBV infected 
parents or siblings, immunosuppression or taking im-
munosuppressive medications, as well as their HBV vac-
cination status (time of receiving the initial dose, time of 
the last dose and more shots after primary vaccination), 
weight, height, and smoking status. We categorized the 
participants to six groups based on injection time from 
last shot (not-vaccinated (none), vaccinated at birth only 
(at birth), more than 10 years (˃ 10), five to 10 years (5 to 
10), less than five years (˂ 5), and a group who couldn’t re-
call their history of vaccination (can’t recall)). The study 
received approval from the Qazvin University of Medical 
Science ethical board. The participants were enrolled 
after obtaining a written consent, and additional doses 
were offered to all participants who didn’t have anti-HBs 
of > 10 mIU/mL. Two hundred and seventy students were 
asked to complete the questionnaire and return it within 
four days. With a response rate of 83%, 255 out of 270 stu-
dents returned the questionnaires. Blood samples were 
collected from all participants. Serum was separated and 
stored at -20°C. Next, anti-HBs was measured by anti-HBs 
enzyme-linked immunosorbent assay (ELISA) kit (Pishtaz 
Teb-HBs-Ab-96). Serum samples with different concentra-
tions of anti-HBs antibody were repeatedly tested both 
for intra-assay (within one kit) and inter-assay (between 
kits). Intra-assay variability (coefficient of variation pre-
sented by percentages) was 3.9 to 10% and inter-assay vari-
ability was 3.7 to 9.1% (28). Participants were considered 
immune if they had an anti-HBs of > 10 mIU/mL. Descrip-
tive and analytical tests were performed using the SPSS® 
software version 19 (SPSS Inc., Chicago, Ill, USA). Continu-
ous variables were summarized as means (or geometric 
mean) ± standard deviation (SD) and categorical vari-
ables as frequencies and percentages, unless otherwise 
stated. The chi square or Fisher’s exact tests were used 
for nominal categorical variables. Analysis of variance 
(standard or nonparametric, as required) was used to test 
for the association between continuous outcomes and 
nominal categorical variables. Post hoc analysis (Bonfer-
roni test) was used to determine the specific nature of 
significant analysis of variance (ANOVA) results. A binary 
logistic regression analysis was used to identify indepen-
dent predictors of anti-HBs positive status (method = 
enter) among the students. A variable was entered into 
the model if the significance level of its F value was less 
than 0.05 and was removed if the significance level was 
greater than 0.1. A P value of < 0.05 was considered statis-
tically significant.
4. Results
A total of 255 participants including 96 medical, 82 nurs-
ing and 77 obstetrics students were enrolled. Only 6.3% of 
the participants had previous contact with a chronic HBV 
infected person. None had ever received blood products 
and had evidence of immunosuppression and no one 
was taking immunosuppressive medications at the time 
of study (Table 1). Vaccination coverage rate (defined as 
the percentage of students who had received three or 
more doses of HB vaccine) was 74.1%, while 94.5% had re-
ceived at least one shot.
About 41% of students were immunized at birth and 
34.1% (87) received primary series vaccination during the 
recent five years (Table 1). Almost all (except one) students 
who were immunized at birth, completed three doses, 
among them 3% received a booster dose after the pri-
mary series. In the other participants, 18 out of 151 (12.0%) 
received only one shot and 22 (14.6%) received two doses 
(26.5% were determined as having received incomplete 
vaccination) (Table 2).
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Table 1.  Distribution of Protective Immunity Status Among the Two Hundred and Fifty-Five Iranian Students
Characteristics Immune Status (Anti-HBs > 10) Count, % P Value (Chi-Square Test)
Positive Negative Total
Age group, y 0.004 a
18 - 20 69 91 160
≥ 21 58 36 94
Sex 0.65
Male 31 (25.0) 36 (27.5) 67 (26.3)
Female 93 (75.0) 95 (72.5) 188 (73.7)
Overweight (based on BMI) 0.44
Yes 24 29 53
No 99 92 191
Marital status 0.46
Single 111 (89.5) 114 (87.0) 225 (88.2)
Married 13 (10.5) 17 (13.0) 30 (11.8)
Number of individuals in the family 0.20 b
3 - 4 38 (34.5) 47 (39.8) 85 (37.3)
5 28 (25.5) 39 (33.1) 67 (29.4)
6 21 (19.1) 11 (9.3) 32 (14.0)
7 12 (10.9) 10 (8.5) 22 (9.6)
≥ 8 11 (10.0) 11 (9.3) 22 (9.6)
Discipline of study 0.02 a
Medicine 57 (46.0) 39 (29.8) 96 (37.6)
Nursing 32 (25.8) 50 (38.2) 82 (32.2)
Obstetric 35 (28.2) 42 (32.1) 77 (30.2)
History of contact 0.40
Yes 10 (8.1) 6 (4.6) 16 (6.3)
No 102 (82.3) 107 (82.3) 209 (82.3)
Can’t recall 12 (9.7) 17 (13.1) 29 (11.4)
Injection time from last shot 0.00 a
None 1 (0.8) 4 (3.1) 5 (2.0)
At birth 33 (26.6) 71 (54.2) 104 (40.8)
> 10 4 (3.2) 11 (8.4) 15 (5.9)
5 to 10 years 23 (18.5) 5 (3.8) 28 (11.5)
≤ 5 years 57 (46.0) 30 (22.9) 87 (34.1)
Can’t recall 6 (4.8) 10 (7.6) 16 (6.3)
Booster dose 0.00 a
Yes 81 (63.3) 42 (33.1) 123 (48.2)
No 42 (32.8) 76 (59.8) 118 (46.3)
Can’t recall 5 (3.9) 9 (7.1) 14 (5.5)
a  The chi-square statistic is significant at the 0.05 level.
b  Chi-square for trend.
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Table 2.  Geometric Mean Level of Anti-HBs Titer of Students Based on Injection Time From Last Shot and Booster Dose (Forgetful 
Students Were Excluded)
Time From Last Shot Booster Dose P Value
Yes No Total
Count, % Mean (SE) a Count, % Mean (SE) Count, % Mean (SE)
None 0 (0.0) - 5 (4.3) 0.401 (0.40) 5 (2.1) 0.401 (0.40) -
At birth 3 (2.5) 0.672 (0.58) 101 (86.3) 0.836 (0.10) 104 (43.5) 0.831 (0.10) 0.781
> 10 year ago 13 (10.7) 0.854 (0.31) 2 (1.7) 0.887 (0.07) 15 (6.3) 0.858 (0.27) 0.968
5 to 10 years 24 (19.7) 1.889 (0.18) 4 (3.4) 2.396 (0.21) 28 (11.7) 1.962 (0.16) 0.274
≤ 5 year 82 (67.2) 1.727 (0.12) 5 (4.3) 0.627 (0.55) 87 (36.4) 1.664 (0.12) 0.031 b
a  Mean: geometric mean level of anti-HBs titer, SE: standard error.
b  The t test statistic was significant at the 0.05 level.
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Figure 1. Comparison of Geometric Mean of Anti-HBs Titer According to 
Two Important Dependent Variables
Younger students (18 - 20 years) had significantly low-
er anti-HBs positivity rate than the older healthy adult 
group (≥ 21 year); 69/160 (43.1%) versus 58/94 (61.7%), P 
= 0.004 (Table 1). About half of the participants didn’t 
show serological evidence of protective immunity. Low 
or undetectable anti-HBs level were found in 82/119 
(68.9%) of students who had their last shot more than 
10 years ago (including at birth) and 35/115 (30.4%) with a 
vaccination history of five years or less (P value < 0.001) 
(Figure 1).
Anti-HBs of lower than 10 mIU/mL was found in 67/104 
(64.4%) of students who were immunized at birth. Also, 
geometric mean level of anti-HBs titer among students 
who received a primary series of vaccine at birth (mean 
= 0.83, SD = 1.01) was significantly lower than students 
who had started vaccination at an older age (1.52 ± 1.14) 
(mean difference = -0.69, P < 0.001). Also, ANOVA for 
geometric mean of anti-HBs titer showed significant 
differences between the six groups based on injection 
time from last shot (P < 0.001) (post-hoc pairwise com-
parisons showed that the “geometric mean of anti-HBs 
titer” had increased at < 5 year group (P < 0.001) and the 
5 to 10 year group (P < 0.001) compared to at birth, also 
it was different at < 5 year group compared with the 5 
to 10 year group (P < 0.001). It shows that the “geomet-
ric mean of anti-HBs titer” persistently decreased after 
birth (Table 3).
The lowest rate of non-protective level belonged to par-
ticipants with complete three doses and a booster ad-
ditional shot (27.1%). The ANOVA for geometric mean of 
anti-HBs titer showed significant differences among the 
three college students (P < 0.001); post hoc comparisons 
indicated a P value of < 0.001 for medicine versus nursing 
students, and 0.02 for medicine versus obstetric students 
(Table 3). Also, protective immunity proportion of nurs-
ing and obstetrics students was significantly lower than 
medical students (Table 1). The final model for indepen-
dent predictors of anti-HBs positive status was made by 
a binary logistic regression analysis. The model included 
presence of a booster dose, injection time from last shot 
and discipline of study (Table 4).
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Table 3.  Multiple Comparisons of Geometric Mean of Anti-HBs Titer (mIU/mL) With Bonferroni Test
Variables Mean Difference Std. Error P Value 95% Confidence Interval
Lower Bound Upper Bound
Discipline of Study
Medicine
Nursing 0.639 a 0.166 0.000 0.24 1.04
Obstetric 0.462 a 0.169 0.020 0.05 0.87
Nursing
Medicine -0.639 a 0.166 0.000 -1.04 -0.24
Obstetric
Nursing 0.176 0.175 0.941 -0.24 0.60
Time From Last Shot
At birth
≤ 5 years -0.833 a 0.151 0.000 -1.28 -0.38
5 to 10 years -1.130 a 0.222 0.000 -1.78 -0.47
> 10 -0.027 0.288 1.000 -0.88 0.82
None 0.430 0.478 1.000 -0.98 1.84
Can’t recall -0.071 0.280 1.000 -0.90 0.75
a  The mean difference was significant at the 0.05 level.
Table 4.  Independent Variables Associated With Anti-HBs Positive Status (Method = Enter)
Model 95% Confidence Interval for EXP (B) P Exp (B)
Lower Upper
Step 1 a
Discipline of study 0.022 b
Discipline of study (1) 0.241 0.973 0.042 b 0.484
Discipline of study (2) 0.611 2.571 0.537 1.254
Booster dose (1) 0.344 2.138 0.742 0.858
Injection time from last shot 0.028 b
Injection time from last shot (1) 0.157 41.599 0.510 2.557
Injection time from last shot (2) 1.399 8.841 0.008 b 3.517
Number of doses of vaccines 0.353 0.938 0.027 b 0.576
Age (1) 0.891 3.411 0.105 1.743
Constant 0.391 2.123
a  Variables entered in step 1: age, booster dose, injection time from last shot, discipline of study and number of doses of vaccines.
b  P < 0.05.
5. Discussion
In our study, only half the participants showed serologi-
cal evidence of protective immunity. Also, booster dose, 
injection time from last shot, and discipline of the study 
have been identified as the most important independent 
predictors of anti-HBs positive status.
Numerous studies on various Iranian populations have 
been conducted over the past few years to investigate the 
protection provided by HB vaccine, yet the participants 
were not students of medical sciences (29-32). The results 
of this study are important in determining the ongoing 
and long-term protection provided by HB vaccine and 
selecting the best strategy for medical students’ vaccina-
tion. The coverage rate was 74.1% in our study. This rate 
was based on the number of students who received vac-
cine at birth time, throughout a campaign or from other 
sources such as private centers. After 20 years of imple-
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mentation, coverage rate for the cohort of adolescents 
who were born from 1989 to 1992 has reached 62% in 1993, 
and 74% at present (32, 33). Similarly, Alavian et al. in 2009, 
using administrative data estimated the vaccination cov-
erage rate as 70%. They also indicated that 74.5% and 78.3% 
received at least two doses and one dose of the vaccine, 
respectively (6). The current study showed considerable 
rates of one or two doses of vaccine (94.5% and 82.7% of 
students, respectively) that were higher than the men-
tioned study.
Although many studies have shown a reverse associa-
tion between obesity and immune response to hepatitis 
B vaccination (34, 35), our study did not reveal such find-
ing. A possible explanation may be high body mass index 
(BMI) in some students at the time of study while they 
had normal BMI at the time of vaccination.
Our study found low or undetectable anti-HBs in 64.4% 
of junior students who were immunized at birth. Also, 
anti-HBs levels among students who received a primary 
series of vaccine at birth were significantly lower than 
students who had started vaccination at an older age; 
this may be due to a longer time between seroconversion 
and measurement in the first group. Results of some oth-
er studies were similar (20). It is also important to con-
sider that the function of the immune system in infants 
is less developed than in older children and adults (19). 
Another explanation for this difference is “vaccination 
boosting” (36). In our study, the highest protective levels 
belonged to students who received the complete three 
doses and an additional shot of vaccine. This finding en-
forces the validity of late suggestion. Evidence of natural 
boosting has been demonstrated in HBV endemic areas 
(37). In this study, pre-entrance exposure to HBV-infected 
people (in the household and community) was low. Thus, 
opportunity for stimulation of immune memory by 
“natural boosting” were likely uncommon. In this study, 
vaccinated students who received the three-dose series 
and an additional shot had the highest anti-HBs levels. 
This finding is in agreement with other reports (34, 38). 
As our study indicated, medical students had a better HB 
immune status than other students. Enrolling students 
to medical faculties in Iran is based on passing a competi-
tive nationwide entrance exam for high school graduates 
(39). The difference between medical students and other 
disciplines might be explained by differences in their 
socio-economic situations including their place of birth 
and education that had a systematic difference (most of 
the medical students were based in Tehran while others 
were mostly from Qazvin and other provinces). More 
studies are needed to determine other affecting factors.
This study had some limitations. The exact dosage, 
brand, and type of primary series vaccines of our par-
ticipants were unknown, and it has been widely accepted 
that anti-HBs levels could be affected by these factors. 
Also, we collected BMI data to find the probable associa-
tion between obesity and poor HB vaccine response, yet 
in the end this was not possible because vaccination was 
done in the past, for which we didn’t have the BMI data.
This study showed a lower anti-HBs level among stu-
dents who were vaccinated during infancy compared 
to those vaccinated as older children or adolescents. 
Although, serological testing should be performed for 
all trainees who are at risk of occupational exposure (to 
guide post-exposure prophylaxis) yet anti-HBs testing af-
ter administration of an additional dose of vaccine may 
be better and more cost-effective than a preliminary sero-
logical testing. This is more important for students with a 
history of vaccination for more than ten years, especially 
those immunized at birth (due to lack of serological evi-
dence of protective immunity). Therefore, we offer an 
early administration of vaccine at the time of entrance to 
university and subsequent measurement of anti-HBs lev-
els one to two months later. Also, trainees with an incom-
plete vaccination and high risk activities for exposure to 
blood or other infectious body fluids may not be protect-
ed and should complete the vaccination series.
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